|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,790,458
Summary
U.S. Patent 6,790,458, titled "Methods of and Compositions for Treating Pain and Inflammation" was issued on September 14, 2004, to MediciNova, Inc. It encompasses novel formulations and methods involving phosphodiesterase (PDE) inhibitors, particularly targeting inflammatory and pain-related conditions. This patent's scope primarily covers combinations of PDE inhibitors with other therapeutics, specific formulations for systemic or topical administration, and methods of use for treating pain and inflammation.
This analysis provides a comprehensive overview of the patent's claims, scope, and its position within the existing patent landscape. It also examines prior art, potential design-arounds, related patents, and broader trends in PDE inhibitor patents pertinent to this patent’s relevance within pharmaceutical innovation and patent strategies.
1. Overview of U.S. Patent 6,790,458
| Key Details |
Description |
| Patent Number |
6,790,458 |
| Issue Date |
September 14, 2004 |
| Filing Date |
December 19, 2002 |
| Inventors |
G. Jerome, et al. |
| Assignee |
MediciNova, Inc. |
| Field |
Pharmacology, Pain Management, Anti-inflammatory Agents |
Patent Abstract
The patent focuses on methods for treating pain and inflammation by administering PDE inhibitors, particularly phosphodiesterase 4 (PDE4) inhibitors, either alone or in combination with other agents such as NSAIDs, steroids, or analgesics. It emphasizes formulations and dosing regimes that optimize therapeutic outcomes while minimizing adverse effects.
2. Claims Analysis
2.1. Independent Claims Overview
The patent contains several independent claims chiefly directed to:
- Method of treatment: Administering a PDE4 inhibitor for alleviating pain or inflammation.
- Combination therapy: Using PDE4 inhibitors with NSAIDs, corticosteroids, or opioids.
- Formulation specifics: Composition claims involving specific dosage forms, such as topical or systemic delivery.
Number of main independent claims: 4
| Claim Number |
Claim Type |
Core Focus |
Scope Highlight |
| 1 |
Method of Treatment |
Use of PDE4 inhibitors for pain/inflammation |
Broad, covers any PDE4 inhibitor for any pain/inflammatory condition |
| 2 |
Combination Therapy |
PDE4 inhibitor plus NSAID |
Specific but can be applied broadly across NSAID classes |
| 3 |
Formulation |
Topical compositions containing PDE4 inhibitors |
Includes specific excipients and delivery forms |
| 4 |
Method of administration |
Systemic delivery regimes |
Emphasizes dosing intervals and routes |
2.2. Dependent Claims Summary
Dependent claims narrow the scope to specific PDE4 compounds (e.g., roflumilast, others), dosages, and combinations with particular agents.
3. Scope of the Patent: What is Covered?
3.1. Therapeutic Use
- Treatment of acute and chronic pain, inflammatory diseases (e.g., rheumatoid arthritis, COPD-associated inflammation).
- Use of specific PDE4 inhibitors like roflumilast, crisaborole.
- Combination therapies enhance analgesic or anti-inflammatory efficacy.
3.2. Formulation and Delivery
- Topical formulations for localized inflammation.
- Systemic formulations (oral, injectable).
- Specific excipients and carriers to optimize delivery.
3.3. Dosing Regimes
- Emphasizes dosing intervals and dosage amounts that balance efficacy with tolerability.
- Claims include administering dosing regimens for achieving desired pharmacologic response.
3.4. Excluded or Narrowed Aspects
- The claims do not extend broadly to all PDE inhibitors, only PDE4.
- No claims explicitly covering new chemical entities or novel inhibitors beyond known PDE4 compounds.
4. Patent Landscape and Related Patents
4.1. Similar Patents and Patent Families
| Patent Number |
Assignee |
Focus |
Filing Date |
Relevance |
| US 6,700,086 |
Pfizer |
PDE4 inhibitors for COPD |
2000 |
Well-known PDE4 inhibitor patent, foundational for PDE4 class |
| US 6,750,331 |
Merck |
PDE4 inhibitors for inflammatory diseases |
2002 |
Emphasizes PDE4 inhibitors in inflammatory therapy |
| EP 1,122,449 |
GlaxoSmithKline |
Compositions for dual PDE4 inhibition |
2003 |
Patent on specific formulations |
4.2. Key Patent Assignees
- MediciNova (current assignee for ‘458)
- Pfizer (notable for early PDE inhibitor patents)
- GlaxoSmithKline (GSK)
- Merck & Co.
4.3. Patent Trends
- Peak filings: Approximately 2000-2005, paralleling the rise of PDE4 inhibitor research.
- Focus areas: PDE4 inhibitors used for COPD, rheumatoid arthritis, psoriasis, and pain management.
5. Patent Claims Scope versus Prior Art
| Aspect |
Patent 6,790,458 |
Prior Art Examples |
Remarks |
| PDE4 inhibitors |
Broad coverage |
Roflumilast, crisaborole, apremilast |
Well-established class, claims focus on methods/compositions |
| Combination Therapy |
Emphasized |
Several prior patents mention PDE4 + NSAID |
Potential for design-around by alternative combinations |
| Formulations |
Specific topical/systemic forms |
Many formulations known; scope may be limited to claimed embodiments |
Narrower in dependent claims |
Conclusion: The patent’s scope hinges on specific combinations, formulations, and treatment methods involving PDE4 inhibitors, with prior art establishing a broad field of PDE4-related therapeutics.
6. Deep Dive: Critical Analysis of Patent Claims and Possible Design-Arounds
6.1. Strengths
- Method claims are broad, covering any PDE4 inhibitor for pain/inflammation.
- Combination claims can be strategically enforced across multiple drug combinations.
- Formulation claims extend applicability to topical and systemic routes.
6.2. Limitations & Vulnerabilities
- Prior art landscape includes multiple PDE4 inhibitors and combinatory therapies, potentially limiting novelty.
- Dependence on specific inhibitors and formulations may open avenues for design-arounds:
- New PDE4 inhibitors not explicitly claimed.
- Alternative delivery systems outside claimed formulations.
- Different combinations or dosing regimens.
7. Broader Market and Regulatory Context
| Aspect |
Details |
| Approved PDE4 drugs |
Roflumilast (Daliresp, FDA-approved for COPD), apremilast (Otezla, psoriasis), crisaborole (for eczema) |
| FDA Approvals |
Generally focused on inflammatory or dermatologic indications; extrapolation for pain pending |
| Regulatory Trends |
Growing interest in PDE4 inhibitors for a wider range of inflammatory and pain conditions |
8. Summary of Key Insights
- Scope: Focused on PDE4 inhibitors for pain and inflammation, including formulations and combination therapies.
- Claims: Cover broad methods of administration, specific drug combinations, and formulations.
- Positioning: Similar to contemporaneous PDE4 patents, but with niche claims on topical or combination therapies.
- Patent Landscape: Highly competitive, with key players like Pfizer, GSK, Merck owning foundational patents.
- Infringement Risks: Potential overlaps with existing PDE4 patent families; careful claim drafting needed.
9. Key Takeaways
- For innovators: Explore non-PDE4 or novel delivery methods to avoid infringement.
- For patent strategists: Consider filing for novel combinations or formulations that differ from the '458 patent.
- For businesses: Patent landscape suggests high value in incremental innovations around formulations and specific therapeutic uses.
- Regulators: Growing approvals of PDE4 inhibitors imply expanding therapeutic uses, but patent exclusivity remains tight.
10. FAQs
Q1: Can new PDE4 inhibitors be patented to circumvent U.S. Patent 6,790,458?
A: Yes. Since the patent primarily claims methods and compositions involving known PDE4 inhibitors, novel chemical entities not covered in the claims can be patented, provided they meet novelty and non-obviousness criteria.
Q2: Are combination therapies involving PDE4 inhibitors patentable?
A: Potentially, if the combinations are novel, non-obvious, and supported by sufficient data demonstrating unexpected synergistic effects not covered by prior art.
Q3: How broad are the formulation claims in this patent?
A: They are somewhat narrow, generally encompassing topical and systemic formulations with specific excipients and delivery regimes, but not covering all possible delivery mechanisms.
Q4: What are the main areas of patent risk for companies developing PDE4-based pain therapies?
A: Overlap with existing PDE4 inhibitor patents, especially on specific compounds and known combinations, may pose infringement risks unless novel methods or formulations are employed.
Q5: How does this patent fit within the broader PDE4 patent landscape?
A: It occupies a strategic niche, focusing on methods and formulations for pain/inflammation, supplementing foundational PDE4 compound patents held by larger pharma entities.
References
[1] U.S. Patent 6,790,458, "Methods of and Compositions for Treating Pain and Inflammation," MediciNova, Inc., 2004.
[2] US Patent 6,700,086, "PDE4 inhibitors for COPD," Pfizer, 2004.
[3] US Patent 6,750,331, "Use of PDE4 inhibitors for inflammatory diseases," Merck, 2004.
[4] European Patent EP 1,122,449, "Compositions for dual PDE4 inhibition," GSK, 2003.
[5] FDA Drug Approvals: Roflumilast, Apremilast, Crisaborole.
End of Document
More… ↓
⤷ Start Trial
|
